Case 4: Cardiovascular risk in renal transplantation

Transplantation

Volumn 75, Issue 9, 2003, Pages 1610-1614

  Hariharan, Sundaram ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CASE REPORT; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPERURICEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; MALE; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL;

EID: 0037910232     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000067887.92034.C3     Document Type: Article

References (39)

1. Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000: 11 Suppl 15: S1-86.
2. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313.
3. Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: what do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853-906.
4. Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158-165.
5. Ponticelli C, Villa M, Cesana B, Montagnino G, Tarantino A. Risk factors for late kidney allograft failure. Kidney Int 2002; 62: 1848-1854.
6. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483.
7. UNOS. UNOS-SRTR 2000. 2000. Ref Type: Generic
8. Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985-992.
9. Lindholm A, Albrechtsen D, Frodin L, Tufveson G, Persson NH, Lundgren G. Ischemic heart disease-major cause of death and graft loss after renal transplantation in Scandinavia. Transplantation 1995; 60: 451-457.
10. Kasiske BL. Epidemiology of cardiovascular disease after renal transplantation. Transplantation 2001; 72: S5-S8.
11. Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 1998; 30: 777-788.
12. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605-612.
13. Peschke B, Scheuermann EH, Geiger H, Bolscher S, Kachel HG, Lenz T. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999; 51: 290-295.
14. Opelz G, Wujciak T, Ritz E. Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998; 53: 217-222.
15. Ojo A, Wolfe RA, Agodoa LY et al. Prognosis after primary renal transplant failure and the beneficial effects of repeat transplantation: multivariate analyses from the United States Renal Data System. Transplantation 1998; 66: 1651-1659.
16. Carvalho MF, Soares V. Hyperlipidemia as a risk factor of renal allograft function impairment. Clin Transplant 2001; 15: 48-52.
17. Wissing KM, Abramowicz D, Broeders N, Vereerstraeten P. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464-472.
18. Vincenti F, Jensik SC, Filo RS, Miller J, Pirsch J. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775-782.
19. Friedman AN, Rosenberg IH, Selhub J, Levey AS, Bostom AG. Hyperhomocysteinemia in renal transplant recipients. Am J Transplant 2002; 2: 308-313.
20. Bostom AD, Brown RS, Jr., Chavers BM et al. Prevention of post-transplant cardiovascular disease-report and recommendations of an ad hoc group. Am J Transplant 2002; 2: 491-500.
21. Margreiter R. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741-746.
22. First MR, Gerber DA, Hariharan S, Kaufman DB, Shapiro R. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379-386.
23. Ahsan N, Johnson C, Gonwa T et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245-250.
24. Marchetti P. Strategies for risk reduction and management of posttransplant diabetes mellitus. Transplant Proc 2001: 33: 27S-31S.
25. Vosnides GG. Hepatitis C in renal transplantation. Kidney Int 1997; 52: 843-861.
26. Baid S, Tolkoff-Rubin N, Farrell ML et al. Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. Transplant Proc 2002; 34: 1771-1773.
27. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group. Transplantation 1997; 63: 977-983.
28. Ligtenberg G, Hene RJ, Blankestijn PJ, Koomans HA. Cardiovascular risk factors in renal transplant patients: cyclosporin A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368-373.
29. Klein IH, Abrahams A, van Ede T, Hene RJ, Koomans HA, Ligtenberg G. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732-736.
30. Taler SJ, Textor SC, Canzanello VJ et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588-1592.
31. Schulak JA, Hricik DE. Steroid withdrawal after renal transplantation. Clin Transplant 1994; 8: 211-216.
32. Flechner SM, Goldfarb D, Modlin C et al. Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 2002; 74: 1070-1076.
33. Hilbrands LB, Demacker PN, Hoitsma AJ, Stalenhoef AF, Koene RA. The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients. J Am Soc Nephrol 1995; 5: 2073-2081.
34. Vathsala A, Weinberg RB, Schoenberg L et al. Lipid abnormalities in cyclosporine-prednisone-treated renal transplant recipients. Transplantation 1989; 48: 37-43.
35. Johnson RW, Kreis H, Oberbauer R, Brattstrom C, Claesson K, Eris J. Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 2001; 72: 777-786.
36. Fernandez-Miranda C, Gomez P, Diaz-Rubio P et al. Plasma homocysteine levels in renal transplanted patients on cyclosporine or tacrolimus therapy: effect of treatment with folic acid. Clin Transplant 2000; 14: 110-114.
37. Quiroga I, Morris-Stiff G, Baboo R, Darby CR, Lord RH, Jurewicz WA. Differential homocysteine levels in renal transplant patients receiving neoral versus tacrolimus. Transplant Proc 2001; 33: 1209-1210.
38. Johnson C, Ahsan N, Gonwa T et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 69: 834-841.
39. Meier-Kriesche HU, Ojo AO, Hanson JA et al. Increased impact of acute rejection on chronic allograft failure in recent era. Transplantation 2000; 70: 1098-1100.